Collegium Pharmaceutical, Inc. · NASDAQ:COLL
Collegium Pharmaceutical — Investor Presentation (June 2021)
20 slides from Collegium Pharmaceutical's investor presentation, Jun 2, 2021
Slide 1: Collegium Pharmaceutical, Inc. Corporate Overview June 2021
Collegium Pharmaceutical, Inc. Corporate Overview June 2021
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates,"
Slide 3: Our Mission: Leader in responsible pain management
Our Mission: We are committed to being the leader in responsible pain management We are a mission-driven organization with an unwavering commitment to people living with pain and the communities we serve
Slide 4: Integrity is Core to our Mission
Integrity is Core to our Mission The core of our mission, and the central tenet of our values, is leading with integrity. As an organization committed to being the leader in responsible pain management, we believe that integrity begins with the equitable, inclusive and dynamic environment we create
Slide 5: Experienced Management Team & Board of Directors
Experienced Management Team & Board of Directors Joseph Ciaffoni President, CEO & Board Member Alison Fleming, Ph.D. EVP & Chief Technical Officer Inventor of DETERx® Colleen Tupper EVP & Chief Financial Officer Richard Malamut, M.D. EVP & Chief Medical Officer Scott Dreyer EVP & Chief Commercial Of
Slide 6: Strong Corporate Culture
Strong Corporate Culture Commitment to our Core Values and DE&I D I E A Uphold Integrity Embrace Differences Encourage Expression Be Accountable External Recognition of our Culture Corporate Social Responsibility Efforts
Slide 7: Our Strategy
Our Strategy Deliver on our missionICreate value for shareholders Maximize the value of our differentiated portfolio of pain products Achieve our near-term operational and financial goals Invest in our long-term growth
Slide 8: Focus on 2021 Objectives
Focus on 2021 Objectives Drive revenue growth from Xtampza® ER Achieve stable profit contributions from Nucynta® franchise Leverage current cost structure, generate cash Deploy balance sheet in disciplined manner Seek opportunities to enhance portfolio long-term
Slide 9: Addressing a Need for Differentiated Pain Products
Addressing a Need for Differentiated Pain Products ~50M Americans experience some form of chronic or severe disabling pain.1 Chronic pain leads to over $560 billion in healthcare and productivity costs each year.2 The FDA has encouraged development of prescription opioids with abuse- deterrent formu
Slide 10: Our Differentiated Pain Portfolio
Our Differentiated Pain Portfolio Viewed Favorably by HCPs & Strong Intent to Prescribe1 LABEL & ACCESS DIFFERENTIATIONPRODUCT DIFFERENTIATION Extended-release, oral oxycodone Indicated for pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative tr
Slide 11: Xtampza ER: Our Core Growth Engine
Xtampza® ER: Our Core Growth Engine EFFICACY Powerful Pain Relief of ER Oxycodone 12-Hour Dosing DIFFERENTIATED LABEL VS. OXYCONTIN® Comparative PK Data Versus OxyContin®1 Maintains PK Profile Designed to maintain its PK profile even when manipulated1 Abuse-Deterrent Labeling Only ER oxycodone with
Slide 12: Xtampza ER: Immediate Acceleration in 2021
Xtampza® ER: Immediate Acceleration in 2021 Xtampza® ER has Achieved Q1’21 Growth of 11% Q/Q Growth3%10%3%1%2%11% YTD Share Growth of +5.5 Points Outpaces Early 2020 Share Growth1 175 TRx (000’s) 125 100 75 124137142143145 161 35% OER Share 25% 20% 15% 19.0% 22.6% 25.1% 30.6% Dec-19 Jan-20 Feb-20 Ma
Slide 13: 2021 Xtampza ER Growth Supported by Broad Market Access
2021 Xtampza® ER Growth Supported by Broad Market Access Coverage 2021 Xtampza® ER Coverage: Commercial Plans: 83% of lives covered1 Medicare Part D Plans: 57% of lives covered1 Xtampza® ER is covered through Exclusive & Parity Contracts for ~55% of lives in 20211 Sources: 1: MMIT Xtampza® ER data A
Slide 14: Xtampza ER Positioned for Next Phase of Growth
Xtampza® ER Positioned for Next Phase of Growth Goal for Xtampza® ER: Secure path for Xtampza® ER market leadership Expect to emerge as #1 branded product in 2023 Strong patent position supports long commercial runway: 19 OB listed patents going out to 2036 TEVA ANDA litigation settled for September
Slide 15: Managing Nucynta Franchise for Stable Profit Contribution
Managing Nucynta® Franchise for Stable Profit Contribution Goal for the Nucynta® Franchise: Contribute stable profits through remaining 5-year lifecycle Leverage our cost structure Five-year commercial runway: IP through mid-2025 Potential pediatric extension would extend exclusivity through end of
Slide 16: Strengthening Our Financial Position
Strengthening Our Financial Position Key Highlights Net Revenue ($m)OPEX Excluding SBC1 ($m) $87.7 $76.5 $78.1$79.2 $76.3 $29.0 $27.5 Record Net Revenue of $87.7m in Q1’21 Reduced Operating Expenses, Excluding Stock-Based Comp, by $35.4 $31.5$33.6$32.1$30.8 $45.0$44.5$47.1$45.5$52.3 Q1Q2Q3Q4Q1 20202
Slide 17: 2021: Focused on Growth & Value Creation
2021: Focused on Growth & Value Creation Maximize the value of ourAchieve our near-term differentiated portfolio ofoperational and pain productsfinancial goals • Drive revenue growth from• Leverage our current cost structure Xtampza® ER‒ Revenue growth • Stable Nucynta® Franchise‒ Profitability prof
Slide 18: Disciplined Approach to Business Development
Disciplined Approach to Business Development Favorable position with current in-line portfolio Long runway with Xtampza® ER: 19 OB listed patents through 2036 Stable Profit Contributions from the Nucynta® Franchise through 2025 Strong balance sheet creates flexibility $174m cash balance YE2020 $170-
Slide 19: 2021 Financial Guidance
2021 Financial Guidance1 Xtampza® ER Revenue $155.0 - $165.0 Million Nucynta® Franchise Revenue $185.0 - $195.0 Million Total Operating Expenses $125.0 - $135.0 Million Non-GAAP Adjusted EBITDA2 $170.0 - $180.0 Million Notes 1: This financial guidance, provided by Collegium Pharmaceutical, Inc. in i
Slide 20: 2021: Focused on Growth & Value Creation
2021: Focused on Growth & Value Creation Deliver on our missionICreate value for shareholders OUR STRATEGY Maximize the value of our differentiated portfolio of pain products Achieve our near-term operational and financial goals Invest in our long-term growth 2021 FOCUS 20 Drive revenue growth from
Collegium Pharmaceutical — Investor Presentation (June 2021) on 6ix